| Nov 10 |
Neurogene: Interesting CNS Disease Company, Data Coming Soon
|
| Nov 5 |
Neurogene Secures $200M for Genetic Therapy Development
|
| Nov 4 |
Neurogene Announces Oversubscribed $200 Million Private Placement
|
| Oct 21 |
Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
|
| Aug 17 |
Neurogene's (NASDAQ:NGNE) Earnings Might Be Weaker Than You Think
|
| Aug 9 |
Neoleukin Therapeutics GAAP EPS of -$1.09 misses by $0.07, revenue of $0.93M
|
| Aug 9 |
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
|
| Aug 7 |
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
|
| Jul 2 |
Neurogene to Participate in BMO Genetic Medicines Summit
|
| Jul 1 |
Neurogene to join Russell 3000 Index
|
